Outcomes after dose escalation of infliximab in Japanese patients with Crohn's disease

被引：0
|
作者：
Sako, M. [1 ]
Kawaguchi, T. [1 ]
Hirayama, A. [1 ]
Fukushi, G. [1 ]
Hayama, K. [1 ]
Fujiwara, T. [1 ]
Yoshimura, N. [1 ]
Takazoe, M. [1 ]
机构：
[1] Social Insurance Cent Hosp, Ctr Inflammatory Bowel Dis, Tokyo, Japan
来源：
JOURNAL OF CROHNS & COLITIS | 2014年 / 8卷
关键词：
D O I：
10.1016/S1873-9946(14)60517-1
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P397
引用
收藏
页码：S231 / S231
页数：1
相关论文
共 50 条
  • [11] Escalation of infliximab maintenance therapy in Crohn's disease
    Corman, Scott
    Issa, Mazen
    Beaulieu, Dawn B.
    Weber, Lydia R.
    Brandenburg, Heather
    Emmons, Jeanne
    Knox, Josh F.
    Skaros, Sue
    Thameem, Danish
    Binion, David G.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2006, 101 (09): : S470 - S470
  • [12] Effectiveness of Ustekinumab Dose Escalation in Patients With Crohn's Disease
    Ollech, Jacob E.
    Normatov, Inessa
    Peleg, Noam
    Wang, Jingzhou
    Patel, Shivani A.
    Rai, Victoria
    Yi, Yangtian
    Singer, Jorie
    Dalal, Sushila R.
    Sakuraba, Atsushi
    Cohen, Russell D.
    Rubin, David T.
    Pekow, Joel
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2021, 19 (01) : 104 - 110
  • [13] Outcomes of infliximab dose escalation in patients with rheumatoid arthritis
    Stanley B. Cohen
    Joel M. Kremer
    Kimberly J. Dandreo
    George W. Reed
    Robert Magner
    Ying Shan
    Shelly Kafka
    Raphael J. DeHoratius
    Lorie Ellis
    Dennis Parenti
    Clinical Rheumatology, 2019, 38 : 2501 - 2508
  • [14] Outcomes of infliximab dose escalation in patients with rheumatoid arthritis
    Cohen, Stanley B.
    Kremer, Joel M.
    Dandreo, Kimberly J.
    Reed, George W.
    Magner, Robert
    Shan, Ying
    Kafka, Shelly
    DeHoratius, Raphael J.
    Ellis, Lorie
    Parenti, Dennis
    CLINICAL RHEUMATOLOGY, 2019, 38 (09) : 2501 - 2508
  • [15] Dose Intensification of Infliximab in Crohn's Disease
    Rodemann, Joseph
    Regueiro, Miguel
    PRACTICAL GASTROENTEROLOGY, 2008, 32 (12) : 8 - 14
  • [16] Infliximab dose intensification in Crohn's disease
    Regueiro, Miguel
    Siemanowski, Benjamin
    Kip, Kevin E.
    Plevy, Scott
    INFLAMMATORY BOWEL DISEASES, 2007, 13 (09) : 1093 - 1099
  • [17] Long-term Durability of Infliximab Treatment in Crohn's Disease and Efficacy of Dose "Escalation" in Patients Losing Response
    Chaparro, Maria
    Panes, Julian
    Garcia, Valle
    Manosa, Miriam
    Esteve, Maria
    Merino, Olga
    Andreu, Montserrat
    Gutierrez, Ana
    Gomollon, Fernando
    Luis Cabriada, Jose
    Angel Montoro, Miguel
    Luis Mendoza, Juan
    Nos, Pilar
    Gisbert, Javier P.
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2011, 45 (02) : 113 - 118
  • [18] LONG-TERM OUTCOMES OF INFLIXIMAB THERAPY FOR JAPANESE PATIENTS WITH CROHN'S DISEASE AT DIFFERENT TIMES OF INITIATION OF INFLIXIMAB ADMINISTRATION
    Tanaka, Hiroki
    Sugiyama, Kohei
    Miyakawa, Maki
    Nasuno, Masanao
    Motoya, Satoshi
    GASTROENTEROLOGY, 2019, 156 (06) : S884 - S885
  • [19] Factors Associated With Ustekinumab Dose Escalation in Patients With Crohn's Disease
    Njie, Cheikh
    Dalal, Rahul S.
    Allegretti, Jessica R.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 : S368 - S368
  • [20] Outcomes 7 Years After Infliximab Withdrawal for Patients With Crohn's Disease in Sustained Remission
    Reenaers, Catherine
    Mary, Jean-Yves
    Nachury, Maria
    Bouhnik, Yoram
    Laharie, David
    Allez, Matthieu
    Fumery, Mathurin
    Amiot, Aurelien
    Savoye, Guillaume
    Altwegg, Romain
    Devos, Martine
    Malamut, Georgia
    Bourreille, Arnaud
    Flourie, Bernard
    Marteau, Philippe
    Vuitton, Lucine
    Coffin, Benoit
    Viennot, Stephanie
    Lambert, Jerome
    Colombel, Jean-Frederic
    Louis, Edouard
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2018, 16 (02) : 234 - +
12345